CD34 and infarction: Nevertheless, Nystedt et al. [2] reported intravenous administration of CD34+ cells after MCAO might improve functional outcome in rats but did not significantly provide neuroprotection, because CD 34+ cells did not reduce infarction size in either transient or permanent MCAO.